Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from PreveCeutical Medical ( (TSE:PREV) ).
PreveCeutical Medical Inc. has announced a new program to develop its Sol-Gel Nose to Brain (N2B) delivery platform for treating Parkinson’s Disease. This program aims to deliver Dopamine and/or L-Dopa directly to the brain, potentially reducing side effects and improving patient outcomes by bypassing the Blood Brain Barrier. The company intends to explore partnerships once proof of concept is established in a preclinical model, underscoring its commitment to cost-effective therapeutic development and positioning itself favorably within the health sciences industry.
More about PreveCeutical Medical
PreveCeutical is a health sciences company focused on developing innovative preventive and curative therapies using organic and nature identical products. The company aims to be a leader in the preventive health sciences sector.
YTD Price Performance: 5.56%
Average Trading Volume: 126,001
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $9.44M
See more data about PREV stock on TipRanks’ Stock Analysis page.